We are live on ! Find out more
CATX icon

Perspective Therapeutics

28 hedge funds and large institutions have $5.49M invested in Perspective Therapeutics in 2014 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

4% more funds holding

Funds holding: 2728 (+1)

0.07% more ownership

Funds ownership: 0.61%0.69% (+0.07%)

2% less capital invested

Capital invested by funds: $5.63M → $5.49M (-$140K)

Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.74%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
5
Reduced
4
Closed
5
Calls
Puts
Net Calls
Net Calls Change

CATX Hedge Fund Activity: Q4 2014 in Review

28 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2014, worth a combined $5.49M — down 2.5% from $5.63M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CATX positions and 5 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $238K. The largest seller was Goldman Sachs, cutting an estimated $104K.

  • 28 institutional investors held Perspective Therapeutics (CATX) as of Q4 2014, up from 27 in Q3 2014.
  • Funds reported $5.49M of Perspective Therapeutics stock for Q4 2014, down 2.5% quarter-over-quarter.
  • 7 funds opened new Perspective Therapeutics positions in Q4 2014 and 5 closed out, a net change of +2 holders.
  • The largest Perspective Therapeutics buyer in Q4 2014 was Bridgeway Capital Management, an estimated $238K added.
  • The largest Perspective Therapeutics seller in Q4 2014 was Goldman Sachs, an estimated $104K sold.

Based on aggregated 13F filings for Q4 2014.